There are currently 252 clinical trials in Spokane, Washington looking for participants to engage in research studies. Trials are conducted at various facilities, including Cancer Care Northwest - Spokane South, Providence Sacred Heart Medical Center and Children's Hospital, Evergreen Hematology and Oncology, PS and Premier Clinical Research. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
A Safety and Pharmacokinetics Study of IDP-122 Lotion in Pediatric Participants With Plaque Psoriasis
NCT03987763
Recruiting
This study is to evaluate the safety, the systemic exposure of halobetasol propionate (HP), and the hypothalamic-pituitary-adrenal (HPA) axis suppression potential for topically applied IDP-122 lotion in pediatric participants with moderate to severe plaque psoriasis.
Gender:
All
Ages:
Between 6 years and 17 years
Trial Updated:
07/25/2023
Locations: Bausch Site 1, Spokane, Washington
Conditions: Psoriasis
Register for Updates
Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission
NCT03267433
Recruiting
This randomized phase III trial studies rituximab after stem cell transplant and to see how well it works compared with rituximab alone in treating patients with in minimal residual disease-negative mantle cell lymphoma in first complete remission. Monoclonal antibodies, such as rituximab, may interfere with the ability of cancer cells to grow and spread. Giving chemotherapy before a stem cell transplant helps kill any cancer cells that are in the body and helps make room in the patient's bone m... Read More
Gender:
All
Ages:
Between 18 years and 70 years
Trial Updated:
06/21/2023
Locations: MultiCare Deaconess Cancer and Blood Specialty Center - Downtown, Spokane, Washington +1 locations
Conditions: CD20 Positive, Mantle Cell Lymphoma
Register for Updates
Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma
NCT03937635
Recruiting
This phase III trial studies how well lenalidomide and dexamethasone works with or without daratumumab in treating patients with high-risk smoldering myeloma. Drugs used in chemotherapy, such as lenalidomide and dexamethasone, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as daratumumab, may induce changes in the body's immune system and may... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/21/2023
Locations: MultiCare Deaconess Cancer and Blood Specialty Center - Downtown, Spokane, Washington +1 locations
Conditions: Smoldering Plasma Cell Myeloma
Register for Updates
Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
NCT02201992
Recruiting
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-sma... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/20/2023
Locations: Cancer Care Northwest - Spokane South, Spokane, Washington +7 locations
Conditions: ALK Gene Rearrangement, ALK Gene Translocation, ALK Positive, Stage IB Non-Small Cell Lung Carcinoma AJCC v7, Stage II Non-Small Cell Lung Cancer AJCC v7, Stage IIA Non-Small Cell Lung Carcinoma AJCC v7, Stage IIB Non-Small Cell Lung Carcinoma AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7
Register for Updates
Study of TU2218 in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
NCT05784688
Recruiting
This study consists of phase 1b and 2a to evaluate safety, Pharmacokinetics, and efficacy of TU2218 in combination with Pembrolizumab in patients with advanced solid tumors. The main purpose of phase 1b is to determine the RP2DC of TU2218 and Pembrolizumab while the main purpose of phase 2a is to evaluate the antitumor efficacy of TU2218 in combination with Pembrolizumab in 3 different selected tumor type cohorts.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/14/2023
Locations: Medical Oncology, Spokane, Washington
Conditions: Solid Tumor
Register for Updates
Clinical Study of a Micro-Implantable Pulse Generator for the Treatment of Peripheral Neuropathic Pain (COMFORT 2)
NCT05870124
Recruiting
This post market study is being conducted to document the comparative effectiveness and safety of peripheral nerve stimulation plus conventional medical management versus conventional medical management alone in the treatment of chronic, intractable peripheral neuralgia of post-traumatic or postsurgical origin. This is a prospective, minimal risk, multi-center, randomized control trial.
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
05/24/2023
Locations: Northwest Pain Care, Spokane, Washington
Conditions: Peripheral Neuralgia, Peripheral Neuropathy, Chronic Pain
Register for Updates
A Study Evaluating the Safety and Efficacy of HB0036 in Subjects With Advanced Solid Tumors
NCT05417321
Recruiting
It is a Phase I/II, Open-label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of HB0036 in Subjects with Advanced Solid Tumors
Gender:
All
Ages:
18 years and above
Trial Updated:
05/08/2023
Locations: Summit Cancer Centers, Spokane, Washington
Conditions: Advanced Solid Tumor, NSCLC
Register for Updates
The Zonisamide and Reinforcement for Reducing Alcohol Use (ZARRA) Study
NCT05134857
Recruiting
A phase II randomized, double-blind, placebo-controlled clinical trial (RCT) to evaluate the ability of zonisamide (ZON) to decrease alcohol use among treatment-seeking adults with an alcohol use disorder (AUD).
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
04/25/2023
Locations: Washington State University, Spokane, Washington
Conditions: Alcohol Use Disorder (AUD)
Register for Updates
Study to Investigate Alternative Dosing Regimens of Belantamab Mafodotin in Participants With Relapsed or Refractory Multiple Myeloma
NCT05064358
Recruiting
This study aims to evaluate alternative dosing regimens of single-agent belantamab mafodotin in participants with relapsed or refractory multiple myeloma (RRMM) to determine if an improved overall benefit/risk profile can be achieved by modifying the belantamab mafodotin dose, schedule, or both.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/10/2023
Locations: GSK Investigational Site, Spokane, Washington
Conditions: Multiple Myeloma
Register for Updates
LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis
NCT02205762
Recruiting
The LCH-IV is an international, multicenter, prospective clinical study for pediatric Langerhans Cell Histiocytosis LCH (age < 18 years).
Gender:
All
Ages:
18 years and below
Trial Updated:
03/21/2023
Locations: Providence Sacred Heart Children's Hospital, Spokane, Washington
Conditions: Langerhans Cell Histiocytosis
Register for Updates
Pharmaceutically-Enhanced Reinforcement for Reduced Alcohol and Smoking
NCT05181891
Recruiting
Using a randomized controlled trial (RCT), the goal of this study is to evaluate the ability of evidence based behavioral treatment (contingency management: CM) to significantly decrease alcohol use and cigarette smoking among treatment-seeking smokers with an alcohol use disorder (AUD) who have initiated pharmacotherapy (varenicline; VC) for smoking cessation.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/07/2023
Locations: Washington State University, Spokane, Washington
Conditions: Alcohol Use Disorder (AUD), Nicotine Use Disorder
Register for Updates
SAD and MAD of Inhaled AR-501 in Health Adults and P. Aeruginosa Infected Cystic Fibrosis Subjects
NCT03669614
Recruiting
This is a Phase 1/2a randomized, double-blind, two-part, dose-ascending, multicenter study of AR-501 (gallium citrate) solution, administered via inhalation, in healthy adult and P. aeruginosa infected cystic fibrosis (CF) subjects. Phase 1 of the study in HV subjects will consist of a single-ascending-dose (SAD) cohort, followed by the HV multiple-ascending-dose (MAD) cohort. Phase 2a of the study in CF subjects will consist of a MAD study design. The study will evaluate the safety and pharmaco... Read More
Gender:
All
Ages:
Between 18 years and 49 years
Trial Updated:
03/07/2023
Locations: Research Site, Spokane, Washington
Conditions: Cystic Fibrosis
Register for Updates